vasopressin antagonist

“Neumora Therapeutics reported positive Phase 1b results for NMRA-511, an oral vasopressin 1a receptor antagonist, showing clinically meaningful reductions in agitation symptoms among Alzheimer’s disease patients. The drug achieved a 15.7-point mean reduction on the Cohen-Mansfield Agitation Inventory (CMAI) total score, with even stronger effects in patients with elevated baseline anxiety, including up to a … Read more